SCM
AGIO icon

SCS Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

SCS Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.7M Hold
612,850
– – 0.21% 66
2026
Q1 		$20.7M Buy
612,850
+14,085
+2% +$399K 0.22% 61
2025
Q4 		$16.3M Hold
598,765
– – 0.17% 78
2025
Q3 		$24M Sell
598,765
-5,320
-0.9% -$200K 0.26% 60
2025
Q2 		$20.1M Sell
604,085
-7,013
-1% -$213K 0.22% 63
2025
Q1 		$17.9M Buy
+611,098
New +$20.3M 0.23% 59

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

SCS Capital Management's AGIO Position: Q2 2026 in Review

SCS Capital Management held its Agios Pharmaceuticals (AGIO) position steady in Q2 2026 at 612,850 shares worth $22.7M. The position accounts for 0.21% of the portfolio, ranked #66.

SCS Capital Management first reported a position in AGIO in Q1 2025 and has held it in 6 quarters since. The position peaked at $24M in Q3 2025. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • SCS Capital Management held 612,850 shares of Agios Pharmaceuticals worth $22.7M as of Q2 2026.
  • SCS Capital Management left its Agios Pharmaceuticals share count unchanged in Q2 2026.
  • Agios Pharmaceuticals made up 0.21% of SCS Capital Management's portfolio in Q2 2026, its #66 holding.
  • SCS Capital Management first reported a position in Agios Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • SCS Capital Management's Agios Pharmaceuticals position peaked at $24M in Q3 2025.
  • 239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.